Haematology Centre, R 51

Stockholm SE-141 86

0 studies enrolling now · 2 studies all time

What they study most

Hematological Malignancies

Studies at this site

• Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling
• A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling